Magnetocardiography for Cardiac Amyloidosis
Official title: A Prospective Study of Magnetocardiography for Disease Detection and Monitoring Treatment Outcomes in Amyloidosis
Run by Mayo Clinic · NCT07218705 · Data updated 2026-11-12
This project tests whether magnetocardiography (MCG) can help diagnose and monitor heart involvement in adults with amyloidosis compared with ECG and other standard tests.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | Mayo Clinic Academic / other |
| Locations | 1 site (Rochester, Minnesota) |
| Status | Recruiting |
| Started | December 3, 2025 |
| Main results expected | November 2027 |
| Study ends | November 2027 |
| Registry record updated | December 22, 2025 |
| Trial ID | NCT07218705 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (age ≥18) with diagnosed or suspected amyloidosis who can consent, lie still for an MCG scan, and do not have thoracic metal implants or active atrial fibrillation are the ideal candidates.
✕Probably not a fit
Patients with implanted cardiac devices, active atrial fibrillation, those who cannot lie supine or remain still, pregnant or breastfeeding individuals, or those unable to travel to Mayo Clinic Rochester are unlikely to benefit from participating.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study uses the SandboxAQ CardiAQ magnetocardiography device to record cardiac magnetic signals in adults with amyloidosis. Participants will undergo MCG scans alongside standard clinical tests such as 12‑lead ECG, and clinical data will be collected to compare diagnostic and monitoring performance. The protocol is non-interventional and conducted at a single site, with enrollment limited to adults who can lie supine and have no active thoracic metal implants or atrial fibrillation. Investigators will analyze correlations between MCG measurements, ECG findings, and clinical indicators of disease progression.
Why it matters
Potential benefit: If successful, MCG could offer a noninvasive, more sensitive way to detect and track cardiac amyloidosis earlier than ECG, potentially guiding care and reducing need for invasive tests.
How similar studies have gone: MCG has shown promise in small studies for detecting cardiac electrical abnormalities, but its application specifically to cardiac amyloidosis is relatively novel with limited prior data.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria 1. Age ≥ 18 years on the date of consent 2. Ability for participant to comply with study requirements 3. Written informed consent Exclusion Criteria 1. Pregnant or breastfeeding 2. Having an active atrial fibrillation episode as seen on most current 12-lead ECG 3. Active thoracic metal implants (including pacemaker, insertable cardiac monitor, or internal defibrillator). 4. External electrical pads or devices (e.g. Pacer pads, ECG electrodes, heart rate patch), that must remain on patient's chest during MCG scan 5. Inability to lie down in a supine/inclined position and stay still on the examination bed 6. Clinical conditions that in the opinion of the Investigator would compromise the safety of the patient or ability to complete the protocol
Where it's running
-
Mayo Clinic in Rochester
Rochester, Minnesota, United States Recruiting
Study contacts
- Principal investigator: Mohamad Alkhouli, M.D., M.B.A. — Mayo Clinic
- Study coordinator: Andy Dang
- Email: dang.phong@mayo.edu
- Phone: 507-255-7752
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Acoramidis for ATTR-CM: Cardiac Imaging Study
This study tests whether acoramidis can improve heart structure and function in people with transthyretin amyloid cardiomyopathy.
-
Heart-Healthy Rehab for Cardiac Amyloidosis
This study tests whether a 5-week supervised cardiac rehabilitation program can help people with cardiac amyloidosis improve exercise capacity and quality of life.
-
SCTC21C plus bortezomib, cyclophosphamide and dexamethasone for newly diagnosed systemic light-chain (AL) amyloidosis
This trial tests whether adding SCTC21C to standard bortezomib‑cyclophosphamide‑dexamethasone (VCd) helps people with newly diagnosed AL (light‑chain) amyloidosis achieve better hematologic responses and outcomes.
-
In-home cancer treatment with remote specialist support for patients in the Florida Panhandle
This program will try giving standard cancer treatments at home to people living in the Florida Panhandle and nearby areas to see if they prefer it and have better treatment satisfaction.
-
18F‑FT8 PET imaging for light‑chain (AL) cardiac amyloidosis
This project tests whether a new PET tracer, 18F‑FT8, can safely and clearly image light‑chain (AL) cardiac amyloidosis in adults with suspected or known disease and in healthy volunteers.
-
Belantamab Mafodotin with a chemotherapy combo for newly diagnosed AL amyloidosis
This study tests whether adding belantamab mafodotin to a regimen of cyclophosphamide, bortezomib, and dexamethasone can help adults with newly diagnosed AL amyloidosis.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.